Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
